Agilent Technologies, Inc. (NYSE:A) Q2 Earnings Top Expectations

Agilent Technologies, Inc. (NYSE:A) shares fell 7%, despite the company reporting Q2 earnings that met Wall Street Expectations. The drop came even on the Chief Executive Officer, Mike McMullen, stating that the company delivered earnings and cash flow growth on top line results.
Neha Gupta

Q2 Earnings Report

The research and development company reported a 10% year over year increase in revenue that came in at $1.21 billion. Agilent’s Life Sciences and Applied Markets registered a 7% increase in revenues that came in at $561 million. The cross lab group recorded a 13% year-over-year increase in revenue that came in at $426 million.

Net income totaled $205 million or 63 cents a share, topping analysts’ expectations as well as last year’s net income of $164 million or 50 cents share. Business exit and divestitures cost the company $8 million as acquisition, and integration costs came in at $4 million.

The company also recorded other net gains of $11 million. Excluding this items and tax benefit of $24 million, the company reported a non-GAAP net income of $212 million.

According to the Chief Executive Officer, net income growth is a testament that they are executing on the growth strategy.

“On the innovation front, we are seeing strong momentum in our newly released products and are continuing to introduce highly differentiated solutions to help our customers advance their work. We are also effectively deploying our capital—the recently closed acquisitions of Genohm and Lasergen, Inc. will add new strategic capabilities to drive future growth,” said Mr. McMullen.

 Q3 Guidance

For the third quarter, Agilent Group expects revenue to range between $1.185 billion and $1.205 billion. GAAP earnings, on the other hand, is expected to range between $0.61 and $0.63 a share. For the full year, the company expects revenue of between $4.85 billion and $4.87 billion. GAAP earnings, on the other hand, should range between $2.63 billion and $2.67 billion.

 Acquisition Drive

In addition, Agilent Technologies has confirmed the completion of the acquisition of Genohm, a Switzerland based company specializing in the development of cloud-based software solutions for laboratory management.

The acquisition is set to enhance the company’s software portfolio with the addition of LIMS and workflow management. Agilent should bring greater context to analytical data with the acquisition while making it easy for scientists to generate results more efficiently.

Genohm joins the company with SLIMs, a digital platform that provides laboratories, with a laboratory management information management system and electronic lab notebook.

Agilent has been aggressive on the acquisition front. Early this month it completed the acquisition of Lasergen an emerging biotechnology company. The acquisition will provide the company with exposure to innovative technologies for the development of DNA sequencing.

In 2016, Agilent Technologies invested in the privately held company and consequently acquired a 48% stake. The company has since invoked a two-year call option that allowed it to acquire the remaining shares for $105 million.

Since the first investment Lasergen and Agilent Technologies have been collaborating on the development of a workflow solution for clinical applications leveraging Lesergens Lightning Terminators.

Don't miss a thing!
Discover what's moving the markets. Sign up for a daily update delivered to your inbox

Latest Articles

See All

Expand Your Knowledge

See All
The content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence checks, apply your own discretion and consult your competent advisors. The content of the website is not personally directed to you, and we does not take into account your financial situation or needs.The information contained in this website is not necessarily provided in real-time nor is it necessarily accurate. Prices provided herein may be provided by market makers and not by exchanges.Any trading or other financial decision you make shall be at your full responsibility, and you must not rely on any information provided through the website. FX Empire does not provide any warranty regarding any of the information contained in the website, and shall bear no responsibility for any trading losses you might incur as a result of using any information contained in the website.The website may include advertisements and other promotional contents, and FX Empire may receive compensation from third parties in connection with the content. FX Empire does not endorse any third party or recommends using any third party's services, and does not assume responsibility for your use of any such third party's website or services.FX Empire and its employees, officers, subsidiaries and associates, are not liable nor shall they be held liable for any loss or damage resulting from your use of the website or reliance on the information provided on this website.
This website includes information about cryptocurrencies, contracts for difference (CFDs) and other financial instruments, and about brokers, exchanges and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and come with a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.FX Empire encourages you to perform your own research before making any investment decision, and to avoid investing in any financial instrument which you do not fully understand how it works and what are the risks involved.